Montelukast for Postinfectious Cough
Ключови думи
Резюме
Описание
Patients in electrical treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . Patients in placebo treatment arm were given placebo tablets(main excipient lactose monohydrate,p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
Дати
| Последна проверка: | 12/31/2014 |
| Първо изпратено: | 01/15/2015 |
| Очаквано записване подадено: | 01/27/2015 |
| Първо публикувано: | 02/01/2015 |
| Изпратена последна актуализация: | 01/27/2015 |
| Последна актуализация публикувана: | 02/01/2015 |
| Действителна начална дата на проучването: | 07/31/2014 |
| Приблизителна дата на първично завършване: | 07/31/2015 |
| Очаквана дата на завършване на проучването: | 09/30/2015 |
Състояние или заболяване
Интервенция / лечение
Drug: Experimental: Montelukast
Фаза
Групи за ръце
| Arm | Интервенция / лечение |
|---|---|
| Experimental: Experimental: Montelukast Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients. | Drug: Experimental: Montelukast Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . |
| Placebo Comparator: Placebo Comparator Patients in placebo treatment arm were given placebo tablets(main excipient lactose monohydrate,p.o., 10mg, q.d.). All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients. |
Критерии за допустимост
| Възрасти, отговарящи на условията за проучване | 18 Years Да се 18 Years |
| Полове, допустими за проучване | All |
| Приема здрави доброволци | Да |
| Критерии | Inclusion Criteria: - Cough is the main or only clinical symptom and was persistent for 3-8 weeks - Chest X-ray reveals no noticeable pathological changes - 18 year old, regardless of gender and ethical background - Not taking angiotensin-converting enzyme inhibitor - Patients must join the programme voluntarily and are able to attend examination and follow-up sessions Exclusion Criteria: - Patients diagnosed with allergic rhinitis, chronic nasosinusitis or bacterial respiratory tract infections - Patients diagnosed with severe reportorial disease of other severe systemic disease - Patients who are allergic to any drugs to be tested - Patients who are non-cooperative during examination sessions or other steps of the trial - Patients who are not able to or refuse to sign consent |
Резултат
Първични изходни мерки
1. Change in Leicester Cough Questionnaire(LCQ) total and domain scores at 10 days post randomisation [10 days]
Вторични изходни мерки
1. cough visual analogue scale scores post randomisation(area under the curve) [10 days]
2. Change in Leicester Cough Questionnaire(LCQ) physical,psychological and social domain scores at 10 days post randomisation [10 days]
